GCTK vs. MBOT, PAVM, XAIR, NVNO, ALUR, SEPA, APYX, CTCX, LNSR, and CTSO
Should you be buying GlucoTrack stock or one of its competitors? The main competitors of GlucoTrack include Microbot Medical (MBOT), PAVmed (PAVM), Beyond Air (XAIR), enVVeno Medical (NVNO), Allurion Technologies (ALUR), SEP Acquisition (SEPA), Apyx Medical (APYX), Carmell (CTCX), LENSAR (LNSR), and Cytosorbents (CTSO). These companies are all part of the "surgical & medical instruments" industry.
Microbot Medical (NASDAQ:MBOT) and GlucoTrack (NASDAQ:GCTK) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, valuation, earnings, institutional ownership, risk, analyst recommendations, profitability and community ranking.
GlucoTrack's return on equity of -149.24% beat Microbot Medical's return on equity.
In the previous week, Microbot Medical had 12 more articles in the media than GlucoTrack. MarketBeat recorded 13 mentions for Microbot Medical and 1 mentions for GlucoTrack. Microbot Medical's average media sentiment score of 0.00 beat GlucoTrack's score of 0.00 indicating that GlucoTrack is being referred to more favorably in the news media.
Microbot Medical received 347 more outperform votes than GlucoTrack when rated by MarketBeat users.
GlucoTrack is trading at a lower price-to-earnings ratio than Microbot Medical, indicating that it is currently the more affordable of the two stocks.
16.3% of Microbot Medical shares are owned by institutional investors. Comparatively, 10.9% of GlucoTrack shares are owned by institutional investors. 10.6% of Microbot Medical shares are owned by insiders. Comparatively, 17.7% of GlucoTrack shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Microbot Medical presently has a consensus target price of $7.00, suggesting a potential upside of 548.15%. Given GlucoTrack's higher probable upside, research analysts plainly believe Microbot Medical is more favorable than GlucoTrack.
Microbot Medical has a beta of 1.63, suggesting that its stock price is 63% more volatile than the S&P 500. Comparatively, GlucoTrack has a beta of 0.13, suggesting that its stock price is 87% less volatile than the S&P 500.
Summary
Microbot Medical beats GlucoTrack on 10 of the 13 factors compared between the two stocks.
Get GlucoTrack News Delivered to You Automatically
Sign up to receive the latest news and ratings for GCTK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GCTK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
GlucoTrack Competitors List
Related Companies and Tools
